Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human DYRK2 Antibodies:
anti-Mouse (Murine) DYRK2 Antibodies:
anti-Rat (Rattus) DYRK2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal DYRK2 Primary Antibody for IHC (p), WB - ABIN391770
Yamashita, Chujo, Tokuishi, Anami, Miyawaki, Yamamoto, Kawahara: Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma. in The Journal of thoracic and cardiovascular surgery 2009
Show all 6 Pubmed References
Results provide evidence that DYRK2 suppresses the proliferation of breast cancer cells and invasion through CDK14 (show CDK14 Antibodies) expression.
Study found that DYRK2 regulates liver metastases of colorectal cancer cells through the activation of EMT (show ITK Antibodies), and that patients with low DYRK2-expressing colorectal cancer liver metastases had worse outcomes than those with high DYRK2-expressing metastases.
our results delineate a novel mechanism of cancer stem cell regulation by the DYRK2-AR-KLF4 (show KLF4 Antibodies) axis. Restoration of the expression and function of DYRK2 is a potential therapeutic strategy against breast cancer stem cells.
lower DYRK2 levels were correlated with tumor sites, advanced clinical stages, and shorter survival in the advanced clinical stages. DYRK2 is a novel prognostic biomarker of human colorectal cancer.
Diminished DYRK2 expression sensitizes hormone receptor (show NR4A1 Antibodies)-positive breast cancer to everolimus by preventing mTOR (show FRAP1 Antibodies) degradation.
Findings indicate direct interaction of dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) with ring finger protein (C3HC4 type) 8 (RNF8) in regulating response to DNA damage.
the downregulated expression of DYRK2 in HCC (show FAM126A Antibodies) tumor tissues could promote the proliferation of hepatocellular carcinoma (HCC (show FAM126A Antibodies)) cells. In addition, reducing DYRK2 expression was associated with poor prognosis and Oxaliplatin resistance in HCC (show FAM126A Antibodies).
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma
DYRK2 may regulate EMT (show ITK Antibodies) through Snail (show SNAI1 Antibodies) degradation in ovarian SA and might be a predictive marker for a favorable prognosis in the treatment of this cancer.
Downregulation of DYRK2 is associated with recurrence in early stage breast cancer.
These results suggest that the phosphorylation of Dpysl2 (show DPYSL2 Antibodies) and Dpysl3 (show DPYSL3 Antibodies) by Cdk5 (show CDK5 Antibodies) and DYRK2 is required for the proper positioning of Rohon-Beard neurons and neural crest cells during neurulation in zebrafish embryos.
Dyrk2 regulates osteoclast fusion in a cell heterotypic manner.
DYRK2 regulates tumor progression through modulation of c-Jun (show JUN Antibodies) and c-Myc (show MYC Antibodies)
DYRK2 belongs to a family of protein kinases whose members are presumed to be involved in cellular growth and/or development. The family is defined by structural similarity of their kinase domains and their capability to autophosphorylate on tyrosine residues. DYRK2 has demonstrated tyrosine autophosphorylation and catalyzed phosphorylation of histones H3 and H2B in vitro. Two isoforms of DYRK2 have been isolated. The predominant isoform, isoform 1, lacks a 5' terminal insert.
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2
, dual specificity tyrosine-phosphorylation-regulated kinase 2